You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 8,569,017

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,569,017

Title:	Method for the preventing and/or treating IL-1 beta lung pathology in mammals by administering a uric acid reducing compound
Abstract:	The present invention is directed to the use of a compound capable of reducing the uric acid level in a mammal for the prevention and/or the treatment of IL-I.beta. driven lung pathology, particularly to treat lung inflammation such as chronic fibrosis, COPD and interstitial fibrosis and other IL-1.beta. driven lung pathologies including those of autoimmune origin. Preferred compounds capable of reducing the uric acid level are selected from the group consisting of xanthine oxidase inhibitors, such as allopurinol, recombinant enzyme uricase and uricosuric compound capable of enhancing uric acid excretion, such as probenecid. The invention further relates to a method for identifying in vitro whether a patient presents an IL-1.beta. driven lung pathology or is at risk to develop an IL-1.beta. driven lung pathology, or for the screening of a compound for treating an IL-1.beta. driven lung pathology.
Inventor(s):	Ryffel; Bernhard (Saint Denis en Val, FR), Couillin; Isabelle (Avaray, FR)
Assignee:	Centre National de la Recheche Scientifique (CNRS) (Paris, FR)
Application Number:	13/119,363
Patent Claims:	1. A method for the prevention and/or the treatment of IL-1.beta. driven lung pathology in a mammal in need thereof, comprising the step of administering an effective amount of a compound capable of reducing the uric acid level in said mammal, wherein said compound is selected from the group consisting of: an uricase, a recombinant uricase, and a functional fragment thereof, and an uricosuric compound, an inhibitor of the tubular organic anion transporter resulting in the augmentation of renal elimination of uric acid, and a pharmaceutically acceptable salt thereof. 2. A method according to claim 1, wherein said IL-1.beta. driven lung pathology is selected from the group consisting of lung inflammation, lung fibrosis and lung pathologies from autoimmune origin. 3. A method according to claim 1, wherein said IL-1.beta. driven lung pathology is a lung inflammation leading to fibrosis and respiratory failure. 4. A method according to claim 1, wherein said recombinant uricase is rasburicase. 5. A method according to claim 4, wherein said uricase is pegylated. 6. A method according to claim 1, wherein said uricosuric compound or inhibitor of the tubular organic anion transporter resulting in the augmentation of renal elimination of uric acid is selected from the group consisting of probenecid, benzbromarone, sulfinpyrazone, thromboxane synthetase inhibitors and thromboxane receptor antagonists. 7. A method according to claim 1, wherein said composition is administered by intravenous injection, by intramuscular injection or orally. 8. A method according to claim 2, wherein lung fibrosis is selected from the group consisting of chronic fibrosis, chronic obstructive pulmonary disease (COPD) and interstitial fibrosis.

Details for Patent 8,569,017

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Sanofi-aventis U.s. Llc	ELITEK	rasburicase	For Injection	103946	07/12/2002	⤷ Try a Trial	2028-09-18
Sanofi-aventis U.s. Llc	ELITEK	rasburicase	For Injection	103946	01/06/2006	⤷ Try a Trial	2028-09-18
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.